

Editorial Board Member: brief biography

Hong Wan



Dr. Hong Wan is currently Executive Director and Head of DMPK/Tox of Shanghai Hengrui Pharmaceutical CO LTD (SHHRP). Prior to joining SHHRP in May 2013, he was Executive Director of DMPK & Bioanalysis Department at a CRO in China, Crown Bioscience Inc (Taicang), for 3 years. Before moving back to China in 2010, he worked for AstraZeneca RD, Mölndal, Sweden for 10 years, from Discovery DMPK & Bioanalytical Chemistry to Lead Generation DMPK and Physical Chemistry, and as a Principal Scientist since 2007. While in this role, he contributed to a number of drug hunting projects as well as led in developing high-throughput DMPK & physicochemical assays. He received his PhD from the Department of Analytical Chemistry, Stockholm University in 1996, and was Associate Professor in the Department of Chemistry, Karlstad University in 2001. He completed his BS degree in 1984 and his MS degree in 1987 in the Analytical Chemistry Department of Lanzhou University and the Lanzhou Institute of Chemical Physics, Chinese Academia of Science, respectively. Dr. Wan has authored and co-authored over 50 publications in peer-reviewed journals and has received invitations to peer review. He is also an Editorial Board member for Expert Opinion on Drug Metabolism and Toxicology, The Open Spectroscopy Journal, and ADMET/DMPK.

©2013 by the authors; licensee IAPC, Zagreb, Croatia. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution licence (<http://creativecommons.org/licenses/by/3.0/>) 